Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Older patients are often deemed unfit for myeloablative conditioning (MAC), which can increase the toxicity associated with transplant, and are relegated to treatment with reduced intensity conditioning (RIC) regimens, which result in a higher incidence of relapse.Orca-T is a high-precision cell therapy biologic that leverages highly purified, polyclonal donor regulatory T cells to control alloreactive immune responses. The specific subsets selected in the Orca-T manufacturing process retain cells with therapeutic benefit while removing those that pose potential risks, allowing for intensification of concomitant chemotherapy and resulting in overall positive outcomes to date in the phase 1b trial.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 64 Source Type: research